Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.

The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.

GSK and Pfizer are both likely to get FDA approval for their respiratory syncytial virus products shortly but Bavarian Nordic is progressing well with its differentiated five RSV-specific antigen jab.

Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.